FundingWatcher
Home / Startups / By venture fund / Novo Holdings portfolio companies

Novo Holdings portfolio companies

Updated 16 Nov 2026

https://www.novoholdings.dk

Novo Holdings portfolio companies
One-time CSV
  • 29 funded companies, 27 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-novo-a-s.csv29 rows × 18 columns
CompanyCityLast roundAmountDate
Claris BiotherapeuticsJersey CitySeries B$118.0M2026-07-28
Windward BioBaselSeries B$165.0M2026-05-04
ADCendoCopenhagenSeries C$75.0M2026-04-14
Bluejay TherapeuticsSan MateoSeries C$182.0M2024-05-09
Reunion NeuroscienceTorontoSeries A$133.0M2025-09-16
Asgard TherapeuticsLundSeries A$32.6M2024-03-14
Doctor AnywhereSingaporeSeries C$40.8M2023-12-06
Terremoto BiosciencesSan FranciscoSeries C$108.0M2026-04-15

8 rows of the CSV in 5 of its 18 columns.

29
Startups
$2.7B
Total raised
5
Funded in the last 12 months
$470.7M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

18 of 29
18 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Claris Biotherapeutics Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. Biotech Jersey City, United States Series B $118.0M 2026-07-28 $225.1M RA Capital Management, Novo Holdings, Janus Henderson Investors +1 1 to 10 2018
Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco, United States Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
ADCendo ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. Biotech Copenhagen, Denmark Series C $75.0M 2026-04-14 $324.6M RA Capital Management, Novo Holdings, Gilde Healthcare +2 51 to 100 2017
Reunion Neuroscience Reunion Neuroscience develops therapeutic treatments for underserved mental health conditions. Biotech Toronto, Canada Series A $133.0M 2025-09-16 $133.0M Novo Holdings, Mitsui Global Investment, MPM Capital +2 1 to 10 2019
Commit Biologics Commit Biologics develops a novel immunotherapy platform for treating cancer. Biotech Aarhus, Denmark Seed $5.7M 2025-01-28 $23.7M Novo Holdings, Innovation Fund Denmark, Bioqube Ventures 11 to 50 2021
Asceneuron Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. Biotech Lausanne, Switzerland Series C $100.0M 2024-07-16 OrbiMed, Novo Holdings, EQT Life Sciences +1 1 to 10 2012
Bluejay Therapeutics Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. Biotech San Mateo, United States Series C $182.0M 2024-05-09 $242.2M RA Capital Management, Wellington Management, Novo Holdings +2 11 to 50 2019
Asgard Therapeutics Asgard Therapeutics is a biotechnology company developing new therapies. Biotech Lund, Sweden Series A $32.6M 2024-03-14 $39.6M Novo Holdings, Industrifonden, Boehringer Ingelheim Venture Fund +2 11 to 50 2018
Elo Life Systems Elo Life Systems is a biotechnology company that studies how food supports human health and wellness. Biotech Durham, United States Series A $20.5M 2024-01-24 $56.5M Novo Holdings, Alexandria Venture Investments, DCVC Bio +2 11 to 50 2006
Hoba Therapeutics Hoba Therapeutics develops a new therapeutic protein for treating neuropathic pain. Biotech Copenhagen, Denmark Series A $24.8M 2023-12-11 European Innovation Council, EIC Accelerator, Novo Holdings +2 1 to 10 2016
Doctor Anywhere Doctor Anywhere is a telehealth company that connects patients with doctors remotely. Health care Singapore Series C $40.8M 2023-12-06 $176.4M EDBI, Square Peg Capital, Novo Holdings +1 501 to 1,000 2016
NMD Pharma NMD Pharma discovers small molecule drugs for neuromuscular disorders. Health care Risskov, Denmark Series B $81.4M 2023-11-15 $171.5M Novo Holdings, Inkef, Jeito Capital +2 11 to 50 1986
Engimmune Therapeutics Engimmune Therapeutics engineers T cell receptor therapies and develops products based on its platform. Biotech Basel, Switzerland Seed $15.8M 2022-05-03 Novo Holdings, Kinled Holding, Pureos Bioventures +1 11 to 50 2021
NBE-Therapeutics NBE-Therapeutics develops oncology treatments for cancer patients. Biotech Basel, Switzerland Series C $22.0M 2020-01-10 $65.7M Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group 11 to 50 2012
Therachon Therachon is a global biotechnology company developing medicines for rare genetic diseases. Biotech Basel, Switzerland Series B $60.0M 2018-08-09 $100.0M Bpifrance, New Enterprise Associates, OrbiMed +2 1 to 10 2014
Inthera Bioscience Inthera Bioscience develops inhibitors of intracellular protein interactions using a proprietary technology platform. Biotech Schlieren, Switzerland Series A $5.5M 2018-06-26 Microsoft Accelerator, Novo Holdings, M Ventures +2 11 to 50 2013
Synosia Therapeutics Synosia Therapeutics develops and commercializes products for unmet needs in psychiatry and neurology. Biotech Basel, Switzerland Series C $30.0M 2010-10-12 $94.0M Novo Holdings, Versant Ventures, 5AM Ventures +2 1 to 10 2006

Table 1. Novo Holdings portfolio companies: the 18 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 29.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
2 Claris Biotherapeutics Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. Biotech Jersey City, United States Series B $118.0M 2026-07-28 $225.1M RA Capital Management, Novo Holdings, Janus Henderson Investors +1 1 to 10 2018
3 Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco, United States Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
4 ADCendo ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. Biotech Copenhagen, Denmark Series C $75.0M 2026-04-14 $324.6M RA Capital Management, Novo Holdings, Gilde Healthcare +2 51 to 100 2017

Table 2. Novo Holdings portfolio companies: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 OrbiMed Private equity firm New York, United States 4 14% 2 Windward Bio, Terremoto Biosciences
2 Export and Investment Fund Government investment office Hellerup, Denmark 4 14% 1 Reduced
3 RA Capital Management Startup incubator Boston, United States 3 10% 2 Claris Biotherapeutics, ADCendo
4 Inkef Venture capital firm Amsterdam, The Netherlands 3 10%
5 HealthCap Venture capital firm Stockholm, Sweden 2 7% 1 ADCendo
6 Boehringer Ingelheim Venture Fund Corporate venture arm Ingelheim Am Rhein, Germany 2 7%
7 Abingworth Private equity firm London, United Kingdom 2 7%
8 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 2 7%
9 M Ventures Corporate venture arm Amsterdam, The Netherlands 2 7%
10 Versant Ventures Venture capital firm Menlo Park, United States 2 7%
11 Janus Henderson Investors Private equity firm London, United Kingdom 1 3% 1 Claris Biotherapeutics
12 Mass General Brigham Ventures Corporate venture arm Cambridge, United States 1 3% 1 Claris Biotherapeutics
13 Blue Owl Private equity firm New York, United States 1 3% 1 Windward Bio
14 Qiming Venture Partners Venture capital firm Shanghai, China 1 3% 1 Windward Bio
15 RTW Investments Hedge fund New York, United States 1 3% 1 Windward Bio

Table 3. Novo Holdings portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 23 79% $2.3B
Biotech 22 76% $2.3B
Software 2 7% $122.1M
Artificial intelligence 1 3% $33.1M
Fintech 1 3%

Table 4. Novo Holdings portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 3 10% $13.2M
Series A 12 41% $24.8M
Series B 7 24% $81.4M
Series C 7 24% $75.0M

Table 5. Novo Holdings portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
Denmark 10 34%
United States 7 24%
Switzerland 7 24%
Canada 1 3%
Sweden 1 3%
Singapore 1 3%
United Kingdom 1 3%
India 1 3%

Table 6. Novo Holdings portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Copenhagen 7 24%
Basel 5 17%
San Mateo 3 10%
Risskov 2 7%
Jersey City 1 3%
Toronto 1 3%
Lund 1 3%
Singapore 1 3%
San Francisco 1 3%
London 1 3%
Aarhus 1 3%
Lausanne 1 3%

Table 7. Novo Holdings portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
July 2026 1 20% $118.0M
May 2026 1 20% $165.0M
April 2026 2 40% $183.0M
February 2026 1 20% $4.7M

Table 8. Novo Holdings portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 5 17% $470.7M
2025 4 14% $161.9M
2024 8 28% $555.7M
2023 5 17% $209.5M
2022 1 3% $15.8M
2021 1 3%

Table 9. Novo Holdings portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 2 7%
2020 to 2022 5 17%
2015 to 2019 12 41%
2010 to 2014 6 21%
Before 2010 4 14%

Table 10. Novo Holdings portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 9 31%
11 to 50 15 52%
51 to 100 2 7%
101 to 250 1 3%
251 to 500 1 3%
501 to 1,000 1 3%

Table 11. Novo Holdings portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many Novo Holdings portfolio companies are on the list?
29, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 29 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Novo Holdings portfolio companies: 29 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 29 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/novo-a-s/